This model-informed progression analysis, together with genetic, functional and translational studies, established SMAD4 as a key regulator of PCA progression in mice and humans. This work led to the development of a clinical test enabling stratification of men with prostate cancer into benign and aggressive groups.
Science
- Science: Tumor Biology & Models
- February 1, 2011